This innovative session covers the HFmrEF/HFpEF podcast series. The session will give you the opportunity to hear from faculty from all 6 podcast episodes. Come learn about key discussion points from the series, test your knowledge with case study polls, and listen to panel discussion between the experts.

While evidence-based therapies continue to expand, substantial implementation gap exists for the real-world application of the treatment guidelines for HFmrEF/HFpEF especially when navigating comorbidities and other treatment barriers. This episode explores how clinicians can translate the guidelines into practical everyday care for patients.

This episode reviews how device-based strategies can complement disease-modifying medical therapy in HF with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). The discussion emphasizes a practical framework: confirm the HF syndrome and phenotype, identify structural or hemodynamic targets, and then consider appropriate device pathways (monitoring, valves, rhythm/conduction, and emerging structural approaches). Listeners will leave with a "when to refer" framework and implementation pearls for real-world practice.

This episode explores the foundational treatment pillars for HFmrEF and HFpEF, emphasizing the clinical rationale behind simultaneous or rapid-sequential initiation of combination guideline-directed medical therapy (GDMT). Experts also address real-world barriers to implementation—such as workflow, access, and coordination—and share practical strategies to accelerate therapy and improve outcomes.

Experts in this episode, explore tools for assessing ischemic stroke and bleeding risks, principles of anticoagulant dosing in atrial fibrillation, and alternative treatments for patients who can't take anticoagulants. This podcast discusses monitoring parameters, reversal agents, and best practices for perioperative anticoagulation management. Listen now for practical insights on optimizing patient care.

In this episode, experts unpack the emerging concept of cardio-kidney-metabolic (CKM) syndrome and its pivotal role in the development and progression of HFpEF and HFmrEF. Listeners will learn how to identify CKM disease states and comorbidities while addressing risk-stratification, interpret diagnostic markers beyond eGFR, and consider integration of evidence-based metabolic therapies (SGLT2 inhibitors, MRAs, GLP-1 receptor agonists) within a multidisciplinary care model.

Experts review definitions, diagnostic testing, risk prediction tools, and phenotypes of HFpEF. Listen to learn about common mimickers of HFpEF, and diagnostic clues and tests to help identify these diagnoses.